{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:50:11Z","timestamp":1793217011572,"version":"4.5.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T00:00:00Z","timestamp":1587168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT153117"],"award-info":[{"award-number":["PJT153117"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000226","name":"Ontario Ministry of Health and Long-Term Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Case reports have described instances of peripheral and central nervous system toxicity during treatment with metronidazole; however, no large-scale studies have examined this association.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a population-based nested case-control study of adults aged 66 years or older living in Ontario, Canada, between 1 April 2003 and 31 March 2017. Cases were individuals who attended hospital for any of cerebellar dysfunction, encephalopathy, or peripheral neuropathy within 100 days of a prescription for either metronidazole or clindamycin. We matched each case patient with up to 10 event-free control subjects who also received metronidazole or clindamycin. We used conditional logistic regression to test the association between metronidazole exposure and neurologic events, with clindamycin as the reference exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 1212 cases with recent use of either metronidazole or clindamycin and 12 098 controls. Neurologic adverse events were associated with an increased odds of metronidazole exposure compared to clindamycin (odds ratio [OR], 1.72 [95% confidence interval {CI}, 1.53\u20131.94]), which persisted after accounting for patient demographics, comorbidities, and other medication exposures (adjusted odds ratio [aOR], 1.43 [95% CI, 1.26\u20131.63]). We found a consistent association limited to either central (aOR, 1.46 [95% CI, 1.27\u20131.68]) or peripheral (aOR, 1.34 [95% CI, 1.02\u20131.76]) nervous system events. Among metronidazole recipients, the overall incidence of neurologic events at 100 days was approximately 0.25%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Metronidazole is associated with an increased risk of adverse peripheral and central nervous system events relative to clindamycin. Clinicians and patients should be aware of these rare but potentially serious adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaa395","type":"journal-article","created":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T15:11:44Z","timestamp":1586185904000},"page":"2095-2100","source":"Crossref","is-referenced-by-count":45,"title":["Metronidazole-associated Neurologic Events: A Nested Case-control Study"],"prefix":"10.1093","volume":"72","author":[{"given":"Nick","family":"Daneman","sequence":"first","affiliation":[{"name":"ICES, Toronto, Ontario, Canada"},{"name":"Sunnybrook Research Institute, Toronto, Ontario, Canada"},{"name":"Division of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"},{"name":"Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Cheng","sequence":"additional","affiliation":[{"name":"ICES, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Gomes","sequence":"additional","affiliation":[{"name":"ICES, Toronto, Ontario, Canada"},{"name":"Li Ka Shing Knowledge Institute, St Michael\u2019s, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guan","sequence":"additional","affiliation":[{"name":"ICES, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad M","family":"Mamdani","sequence":"additional","affiliation":[{"name":"ICES, Toronto, Ontario, Canada"},{"name":"Li Ka Shing Knowledge Institute, St Michael\u2019s, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah E","family":"Saxena","sequence":"additional","affiliation":[{"name":"ICES, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N","family":"Juurlink","sequence":"additional","affiliation":[{"name":"ICES, Toronto, Ontario, Canada"},{"name":"Sunnybrook Research Institute, Toronto, Ontario, Canada"},{"name":"Division of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"},{"name":"Division of Clinical Pharmacology and General Internal Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,18]]},"reference":[{"key":"2021061514012603400_CIT0001","first-page":"22","article-title":"Metronidazole versus anaerobes. In vitro data and initial clinical observations","volume":"117","author":"Tally","year":"1972","journal-title":"Calif Med"},{"key":"2021061514012603400_CIT0002","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1001\/jama.2014.12923","article-title":"Prevalence of antimicrobial use in US acute care hospitals, May-September 2011","volume":"312","author":"Magill","year":"2014","journal-title":"JAMA"},{"key":"2021061514012603400_CIT0003","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/jamainternmed.2016.5651","article-title":"Estimating national trends in inpatient antibiotic use among US hospitals from 2006 to 2012","volume":"176","author":"Baggs","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2021061514012603400_CIT0004","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1176\/ajp.134.3.329-d","article-title":"Side effects of metronidazole","volume":"134","author":"Giannini","year":"1977","journal-title":"Am J Psychiatry"},{"key":"2021061514012603400_CIT0005","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.ijid.2008.03.006","article-title":"Cerebellar ataxia following prolonged use of metronidazole: case report and literature review","volume":"12","author":"Patel","year":"2008","journal-title":"Int J Infect Dis"},{"key":"2021061514012603400_CIT0006","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/WNF.0b013e3182334b35","article-title":"Metronidazole-induced central nervous system toxicity: a systematic review","volume":"34","author":"Kuriyama","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"2021061514012603400_CIT0007","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/0091270010362905","article-title":"Metronidazole-induced encephalopathy: a case report and review of the literature","volume":"51","author":"Bottenberg","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"2021061514012603400_CIT0008","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1017\/S0317167100015870","article-title":"Neurologic complications of metronidazole","volume":"40","author":"Sarna","year":"2013","journal-title":"Can J Neurol Sci"},{"key":"2021061514012603400_CIT0009","doi-asserted-by":"crossref","first-page":"559","DOI":"10.11150\/kansenshogakuzasshi.89.559","article-title":"Clinical characteristics of metronidazole-induced encephalopathy: a report of two cases and a review of 32 Japanese cases in the literature [in Japanese]","volume":"89","author":"Kato","year":"2015","journal-title":"Kansenshogaku Zasshi"},{"key":"2021061514012603400_CIT0010","first-page":"OE01","article-title":"Clinical and neuroradiological spectrum of metronidazole induced encephalopathy: our experience and the review of literature","volume":"10","author":"Roy","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"2021061514012603400_CIT0011","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMicm1505174","article-title":"Images in clinical medicine. Metronidazole-associated encephalopathy","volume":"374","author":"Farmakiotis","year":"2016","journal-title":"N Engl J Med"},{"key":"2021061514012603400_CIT0012","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1503\/cmaj.090591","article-title":"Cases: reversible cerebellar syndrome caused by metronidazole","volume":"181","author":"Sarna","year":"2009","journal-title":"CMAJ"},{"key":"2021061514012603400_CIT0013","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.amjmed.2007.02.028","article-title":"Impact of a fluoroquinolone restriction policy in an elderly population","volume":"120","author":"Mamdani","year":"2007","journal-title":"Am J Med"},{"key":"2021061514012603400_CIT0014","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jamainternmed.2015.2770","article-title":"Variability in antibiotic use across nursing homes and the risk of antibiotic-related adverse outcomes for individual residents","volume":"175","author":"Daneman","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2021061514012603400_CIT0015","doi-asserted-by":"crossref","first-page":"e010077","DOI":"10.1136\/bmjopen-2015-010077","article-title":"Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study","volume":"5","author":"Daneman","year":"2015","journal-title":"BMJ Open"},{"key":"2021061514012603400_CIT0016","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1056\/NEJMoa055191","article-title":"Outpatient gatifloxacin therapy and dysglycemia in older adults","volume":"354","author":"Park-Wyllie","year":"2006","journal-title":"N Engl J Med"},{"key":"2021061514012603400_CIT0017","first-page":"67","article-title":"Coding accuracy of administrative drug claims in the Ontario drug benefit database","volume":"10","author":"Levy","year":"2003","journal-title":"Can J Clin Pharmacol"},{"key":"2021061514012603400_CIT0018","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"2021061514012603400_CIT0019","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2021061514012603400_CIT0020","article-title":"FDA drug safety communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together","author":"US Food and Drug Administration.","year":"2016"},{"key":"2021061514012603400_CIT0021","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1128\/AAC.00753-13","article-title":"Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis","volume":"57","author":"Carroll","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2021061514012603400_CIT0022","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/bmj.2.6087.610","article-title":"Metronidazole neuropathy","volume":"2","author":"Bradley","year":"1977","journal-title":"Br Med J"},{"key":"2021061514012603400_CIT0023","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/BF00686856","article-title":"Metronidazole encephalopathy in rats [in German]","volume":"25","author":"von Rogulja","year":"1973","journal-title":"Acta Neuropathol"},{"key":"2021061514012603400_CIT0024","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1939-1676.2003.tb02452.x","article-title":"Diazepam as a treatment for metronidazole toxicosis in dogs: a retrospective study of 21 cases","volume":"17","author":"Evans","year":"2003","journal-title":"J Vet Intern Med"},{"key":"2021061514012603400_CIT0025","doi-asserted-by":"crossref","first-page":"11731","DOI":"10.1016\/S0021-9258(18)60872-5","article-title":"Generation of nitro radical anions of some 5-nitrofurans, 2- and 5-nitroimidazoles by norepinephrine, dopamine, and serotonin. A possible mechanism for neurotoxicity caused by nitroheterocyclic drugs","volume":"262","author":"Rao","year":"1987","journal-title":"J Biol Chem"},{"key":"2021061514012603400_CIT0026","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ijantimicag.2017.08.033","article-title":"Clinical relevance of metronidazole and peripheral neuropathy: a systematic review of the literature","volume":"51","author":"Goolsby","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2021061514012603400_CIT0027","volume-title":"National Ambulatory Care Reporting System CIHI data quality study of Ontario emergency department visits for 2004\u20132005: executive summary","author":"Canadian Institute for Health Information (CIHI)","year":"2007"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa395\/33373785\/ciaa395.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/12\/2095\/38649278\/ciaa395.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/12\/2095\/38649278\/ciaa395.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T10:02:05Z","timestamp":1623751325000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/72\/12\/2095\/5821517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,18]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,4,18]]},"published-print":{"date-parts":[[2021,6,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa395","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,15]]},"published":{"date-parts":[[2020,4,18]]}}}